Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Implication of the New AJCC pT Classification of SCC of the Lip Comparing With Other Oral Subsites

Full text
Toledo, Loic Monginet [1] ; de Oliveira, Adriana Santos [1] ; Pinheiro, Renan Aguera [1] ; Leite, Ana Kober Nogueira [1] ; de Mello, Evandro Sobroza [2] ; Moyses, Raquel Ajub [1] ; Kulcsar, Marco Aurelio V. [1] ; Dedivitis, Rogerio Aparecido [1] ; Kowalski, Luiz Paulo [1] ; Matos, Leandro Luongo [1]
Total Authors: 10
[1] Univ Sao Paulo, Med Sch, Head & Neck Surg Dept, Sao Paulo - Brazil
[2] Univ Sao Paulo, Med Sch, Pathol Dept, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: LARYNGOSCOPE; v. 131, n. 11, p. E2770-E2776, NOV 2021.
Web of Science Citations: 0

Objective To determine the implication of the new AJCC staging system for pT classification in a cohort of patients with SCC of the lip mucosa and compare it to other oral cavity sites. Methods Retrospective cohort of 744 patients treated between 2002 and 2017, by the Head and Neck Surgery Department of the University of Sao Paulo. Results Of 95 lip patients, 42 had pT upstage (58.1% of pT1 to pT2-3 and 50% of pT2 to pT3). Similar DFS/OS observed for those pT1 maintained or upstaged to pT2-3, pT2 patients upstaged to pT3 presented worse OS (49.4% versus 92.3%, P = .032). The comparison between lip and other mouth topographies, denoted better prognosis for pT1-2, but not for pT3-4a. Lip tumors had lower DOI, rates of perineural/angiolymphatic invasion, nodal metastasis, recurrence, and death. Conclusion The inclusion of DOI to the new pT classification better stratifies patients with SCC of the lip mucosa upstaged to pT3 by assessing inferior OS. Level of Evidence 3 Laryngoscope, 2021 (AU)

FAPESP's process: 16/01740-6 - Proteoglycans profile and micro-RNA expression associated to tumor invasion and prognosis in oral cavity squamous cell carcinoma
Grantee:Leandro Luongo de Matos
Support type: Regular Research Grants